Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Captured Human RANK, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. RAK-H5251) on CM5 chip via Anti-Mouse antibodies surface can bind Human TNFSF11, Fc Tag (Cat. No. RAL-H5265) with an affinity constant of 0.574 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Narlumosbart | JMT-103 | Approved | Shanghai Jmt-Bio Inc | 津立泰, 津立生 | Mainland China | Giant Cell Tumor of Bone | Shanghai Jmt-Bio Inc | 2023-09-05 | Bone metastases; Solid tumours; Osteoporosis; Hypercalcemia; Bone Diseases; Neoplasms; Osteoporosis, Postmenopausal; Multiple Myeloma; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis | Details |
| Denosumab biosimilar (Mabwell) | 9-MW-0311; 9MW0321; 9-MW0321; 9MW-0321; 9-MW-0321; TK-006; MW-032; MW-031; 9MW0311; 9-MW0311; 9MW-0311 | Approved | Jiangsu T-Mab Bio-Pharmaceuticals Co Ltd | 迈利舒, 迈卫健, MAIWEIJIAN, MAILISHU | Mainland China | Osteoporosis, Postmenopausal | Jiangsu T-Mab Bio-Pharmaceuticals Co Ltd | 2023-03-28 | Bone metastases; Solid tumours; Osteoporosis; Osteoporosis, Postmenopausal; Breast Neoplasms; Bone Neoplasms; Giant Cell Tumor of Bone | Details |
| Denosumab biosimilar (Qilu Pharma) | QL-1206 | Approved | Qilu Pharmaceutical Co Ltd | 鲁可欣 | Mainland China | Osteoporosis, Postmenopausal | Qilu Pharmaceutical Co Ltd | 2023-09-28 | Bone metastases; Solid tumours; Osteoporosis, Postmenopausal; Giant Cell Tumor of Bone | Details |
| Denosumab biosimilar (Boan Biopharma/Luye) | LY-01011; BA-1102; BA-6101; LY-06006 | Approved | Shandong Boan Biotechnology Co Ltd | 博洛加, Boluojia, Boyoubei | Mainland China | Osteoporosis, Postmenopausal | Shandong Boan Biotechnology Co Ltd | 2022-11-10 | Bone metastases; Solid tumours; Osteoporosis; Osteoporosis, Postmenopausal; Neoplasms; Giant Cell Tumor of Bone; Bone Neoplasms; Neoplasm Metastasis | Details |
| Denosumab | NSC-744010; AMG-162 | Approved | Amgen Inc | Prolia, Xgeva, Pralia, Ranmark, 普罗力 | EU | Osteoporosis, Postmenopausal | Amgen Europe Bv | 2010-05-26 | Lymphoma, Non-Hodgkin; Bone Cysts, Aneurysmal; Feeding and Eating Disorders; Breast Neoplasms; Giant Cell Tumors; Prostatic Neoplasms; Osteogenesis Imperfecta; Osteosarcoma; Arthropathy, Neurogenic; Giant Cell Tumor of Bone; Bone Neoplasms; Breast Diseases; Thyroid Neoplasms; Lung Neoplasms; Prostatic Neoplasms, Castration-Resistant; Fractures, Bone; Carcinoma, Squamous Cell; Osteoblastoma; Granuloma, Giant Cell; Glucocorticoid-induced osteoporosis; Lymphoma; Metastatic breast cancer; Neoplasm Metastasis; Anorexia Nervosa; Crohn Disease; Carcinoma, Non-Small-Cell Lung; Fibroma; Renal Insufficiency; Solid tumours; Bone metastases; Endocrine Gland Neoplasms; Cataract; Kidney Neoplasms; Hematopoietic stem cell transplantation (HSCT); Hematologic Neoplasms; Parathyroid Neoplasms; Osteoporosis; Bone Diseases, Metabolic; Carcinoma; Pain; Fibrous Dysplasia of Bone; Head and Neck Neoplasms; Hypercalcemia; Arthritis, Rheumatoid; Osteoporosis, Postmenopausal; Colonic Neoplasms; Hodgkin Disease; Neoplasms; Smoldering Mu | Details |
| Denosumab biosimilar(Reliance Life Sciences) | R-TPR-045 | Approved | Reliance Life Sciences | DenosuRel | India | Osteoporosis, Postmenopausal; Bone metastases | Reliance Life Sciences | 2022-02-01 | Bone metastases; Osteoporosis, Postmenopausal | Details |
| Denosumab biosimilar (Sandoz) | GP-2411 | Approved | Novartis Pharma Ag, Sandoz | Jubbonti®, Wyost® | United States | Osteoporosis, Postmenopausal; Osteoporosis; Glucocorticoid-induced osteoporosis | Sandoz, Sandoz Inc | 2024-03-05 | Osteoporosis; Osteoporosis, Postmenopausal; Bone Resorption; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis | Details |
| Denosumab biosimilar (Alphamab) | KN-012 | Approved | Suzhou Alphamab Co Ltd | Mainland China | Osteoporosis, Postmenopausal | Philippine Biological Technology (Jilin) Co Ltd, Alphamab Jilin Co Ltd | 2024-09-03 | Osteoporosis, Postmenopausal | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Denosumab biosimilar (Intas Biopharmaceuticals) | Phase 3 Clinical | Intas Biopharmaceuticals | Osteoporosis, Postmenopausal | Details | |
| Denosumab biosimilar(Shanghai Hansoh) | HS-20090; HS-20090-2 | Phase 3 Clinical | Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd | Solid tumours; Bone metastases; Bone Diseases; Hypercalcemia; Osteoporosis, Postmenopausal; Neoplasms; Multiple Myeloma; Giant Cell Tumor of Bone; Nutritional and Metabolic Diseases | Details |
| Denosumab biosimilar (Teva Pharmaceutical) | TVB-009; TVB-009P | Phase 3 Clinical | Teva Pharmaceutical Industries Ltd | Osteoporosis, Postmenopausal | Details |
| CMAB807 | CMAB-807; CMAB807X | Phase 3 Clinical | Shanghai Biomabs Pharmaceuticals Co Ltd, Shanghai Maitai Yabo Biotechnology Co Ltd | Osteoporosis, Postmenopausal | Details |
| Recombinant human anti-RANKL momoclonal antibody (Qilu Pharmaceutical) | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Neoplasms; Osteoporosis, Postmenopausal | Details | |
| Denosumab biosimilar (GlycoNex) | SPD8; SPD-8 | Phase 3 Clinical | Glyconex Inc | Osteoporosis; Neoplasms | Details |
| Denosumab biosimilar (Hetero Biopharma) | Phase 3 Clinical | Hetero Biopharma Ltd | Solid tumours | Details | |
| Denosumab biosimilar(Curateq Biologics) | BP-16 | Phase 3 Clinical | CuraTeQ Biologics Pvt Ltd | Osteoporosis, Postmenopausal | Details |
| Denosumab biosimilar(Enzene Biosciences) | ENZ-215 | Phase 3 Clinical | Enzene Biosciences Ltd | Osteoporosis, Postmenopausal | Details |
| Denosumab biosimilar (Alvotech Swiss) | AVT03; AVT-03 | Phase 3 Clinical | Alvotech Swiss Ag | Osteoporosis, Postmenopausal | Details |
| Denosumab biosimilar(Mabxience) | Phase 3 Clinical | Mabxience Sa | Osteoporosis, Postmenopausal | Details | |
| Denosumab biosimilar (Hualan Biological Engineering) | Phase 3 Clinical | Hualan Genetic Engineering Co Ltd | Solid tumours; Bone metastases; Osteoporosis, Postmenopausal | Details | |
| Denosumab biosimilar (Gedeon Richter) | RGB-14-P | Phase 3 Clinical | Gedeon Richter Plc | Osteoporosis, Postmenopausal | Details |
| Denosumab biosimilar(Fresenius Kabi) | FKS-518 | Phase 3 Clinical | Fresenius Kabi Swissbiosim Gmbh | Osteoporosis, Postmenopausal | Details |
| Denosumab biosimilar (Samsung Bioepis) | SB-16 | Phase 3 Clinical | Samsung Bioepis Co Ltd | Osteoporosis, Postmenopausal | Details |
| Recombinant anti-RANKL monoclonal antibody(Jiangsu Pacific-Meinuoke) | Phase 3 Clinical | Jiangsu Pacific-Meinuoke Bio-Pharmaceutical Co Ltd | Osteoporosis, Postmenopausal | Details | |
| Denosumab biosimiliar (Celltrion) | CT-P41 | Phase 3 Clinical | Celltrion Inc | Osteoporosis, Postmenopausal | Details |
| LZM-004 | LZM-004 | Phase 1 Clinical | Livzon(Group) Pharmaceutical Factory | Bone metastases | Details |
| Recombinant human anti-RANKL antibody (Innovent Biologics) | IBI-307 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Osteoporosis | Details |
| GB-223 | GB-223; GB223 | Phase 1 Clinical | Genor Biopharma Co Ltd | Solid tumours; Bone metastases; Osteoporosis, Postmenopausal; Bone Neoplasms; Giant Cell Tumor of Bone | Details |
| Recombinant human anti-RANKL antibody (Hisun Pharma) | HS629 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Solid tumours; Bone metastases | Details |
This web search service is supported by Google Inc.
A-Z
